2Litvan I,Goldman JG,Trster AI,et al.Diagnostic criteria for mild cognitive impairment in Parkinson's disease:Movement Disorder Society Task Force guidelines[J].Movement Disorders,2012;27(3):349-56.
3Lill CM,Roehr JT,Mc Queen MB,et al.Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics:The PDGene database[J].PLo S Genetics,2012;8(3):e1002548.
4Muller T,Hellwig R,Muhlack S.Levodopa induces synthesis of nerve growth factor and growth hormone in patients with Parkinson disease[J].Clin Neuropharmacol,2011;34(3):101-3.
5Schapira AH,Mc Dermott MP,Barone P,et al.Pramipexole in patients with early Parkinson's disease(PROUD):a randomised delayed-start trial[J].Lancet Neurol,2013;12(8):747-55.
6Broen MP,Moonen AJ,Kuijf ML,et al.Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease[J].Parkinsonism Relat Dis,2015;21(2):142-6.
7Kataoka H,Tanaka N,Saeki K,et al.Low frontal assessment battery score as a risk factor for falling in patients with Hoehn-Yahr StageⅢParkinson's disease:a 2-year prospective study[J].European Neurol,2013;71(3-4):187-92.
8Hauser RA,Schapira AH,Barone P,et al.Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease[J].European J Neurol,2014;21(5):736-43.
9Mizuno Y,Yamamoto M,Kuno S,et al.Efficacy and Safety of ExtendedVersus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease:A Double-Blind,Randomized Trial[J].Clin Neuropharmacol,2012;35(4):174-81.
10Eggert K,hlwein C,Kassubek J,et al.Influence of the nonergot dopamine agonist piribedil on vigilance in patients with parkinson disease and excessive daytime sleepiness(Pi Vi Cog-PD):an 11-week randomized comparison trial against pramipexole and ropinirole[J].Clin Neuropharmacol,2014;37(4):116-22.
